Analyst firms · H.C. Wainwright · RPHM

H.C. Wainwright RPHM price target and rating history

Reneo Pharmaceuticals Inc. (RPHM) · Health Care

H.C. Wainwright rates Reneo Pharmaceuticals Inc. (RPHM) Neutral with a $1.50 price target, as of its latest action on Dec 15, 2023. It has published 4 rating actions on RPHM since December 2021, including 0 upgrades and 1 downgrade.

Current rating
Neutral
Price target
$1.50
Median target, all firms
Too few
Actions on RPHM
4

H.C. Wainwright price target on RPHM

$31$16$1.5020222023202420252026
H.C. Wainwright price target on RPHM, each point a stated target, December 2021 to December 2023.

Every H.C. Wainwright rating on RPHM

Questions about H.C. Wainwright and RPHM

What is H.C. Wainwright's price target for RPHM?
H.C. Wainwright's latest stated price target for Reneo Pharmaceuticals Inc. (RPHM) is $1.50, from its action on Dec 15, 2023.
What is H.C. Wainwright's rating on RPHM?
H.C. Wainwright rates RPHM Neutral, a neutral rating, as of Dec 15, 2023.
When did H.C. Wainwright last change its view on RPHM?
On Dec 15, 2023, H.C. Wainwright downgrades to Neutral from Buy, price target $30 to $1.50.

More RPHM rating histories

All H.C. Wainwright ratingsRPHM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.